Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stiripentol.

Catherine Chiron1

  • 1INSERM, U663, Service de Neurologie et Métabolisme, Hôpital Necker, 149 rue de Sèvres, 75015 Paris, France. catherine.chiron@nck.aphp.fr

Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|January 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Freediving Lead to Hippocampal Adaptability to Hypoxia and Maintenance of Episodic Memory?

Journal of integrative neuroscience·2025
Same author

Auditory evoked delta brushes involve stimulus-specific cortical networks in preterm infants.

iScience·2025
Same author

Cardiovascular and cerebral hemodynamics during static and dynamic breath-holding.

European journal of applied physiology·2025
Same author

Additional Results from Two Randomized, Placebo-Controlled Trials of Stiripentol in Dravet Syndrome Highlight a Rapid Antiseizure Efficacy with Longer Seizure-Free Periods.

Neurology and therapy·2024
Same author

Brain 18 F-FDG PET reveals cortico-subcortical hypermetabolic dysfunction in juvenile neuropsychiatric systemic lupus erythematosus.

EJNMMI research·2024
Same author

Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.

Epilepsia open·2024
Same journal

Contemporary surgical strategies for resection of intracranial gliomas.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

FGF17 synergistically targets neuronal survival and oligodendrogenesis to restore stroke deficits.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Neurological complications of current and emerging CAR-T cell therapies.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Hemodynamics Beyond Ischemic Zone Underlies Early Neurological Deterioration in Minor Stroke with Large Vessel Occlusion.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same journal

Nervonic acid and the long arc of therapeutic hope in X-linked adrenoleukodystrophy.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
See all related articles

Stiripentol (STP) is an antiepileptic drug effective for Dravet syndrome in children. It enhances GABAergic transmission and inhibits specific CYP enzymes, requiring careful drug interaction management.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Pediatric Neurology

Background:

  • Stiripentol (STP) is an antiepileptic compound with demonstrated in vitro GABAergic transmission enhancement.
  • In vivo, STP acts as a CYP3A4, CYP1A2, and CYP2C19 inhibitor in epileptic patients.
  • Clinical trials revealed disappointing results in adults but specific efficacy in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy and safety of Stiripentol (STP) in pediatric epilepsy syndromes.
  • To investigate the pharmacokinetic interactions of STP with other antiepileptic drugs.
  • To explore the potential of STP in pharmacoresistant partial epilepsy.

Main Methods:

  • Clinical trials in pediatric populations with severe myoclonic epilepsy in infancy (Dravet syndrome).

Related Experiment Videos

  • Compassionate use data from French centers for pharmacoresistant partial epilepsy.
  • In vitro studies on GABAergic transmission and in vivo studies on CYP enzyme inhibition.

    • Main Results:

    • STP demonstrated specific efficacy in Dravet syndrome when combined with valproate and clobazam.
    • STP received orphan drug status in the EU for Dravet syndrome treatment.
    • Compassionate use data suggests potential benefit with carbamazepine in pharmacoresistant partial epilepsy.

    Conclusions:

    • Stiripentol is a valuable therapeutic option for Dravet syndrome in children.
    • Careful consideration of drug interactions and dose adjustments is crucial when using STP.
    • Further research may explore STP's role in other severe pediatric epilepsy forms.